AU2001264801A1 - Diagnosis of alzheimer's disease ldl receptor protein-1 - Google Patents
Diagnosis of alzheimer's disease ldl receptor protein-1Info
- Publication number
- AU2001264801A1 AU2001264801A1 AU2001264801A AU6480101A AU2001264801A1 AU 2001264801 A1 AU2001264801 A1 AU 2001264801A1 AU 2001264801 A AU2001264801 A AU 2001264801A AU 6480101 A AU6480101 A AU 6480101A AU 2001264801 A1 AU2001264801 A1 AU 2001264801A1
- Authority
- AU
- Australia
- Prior art keywords
- disease
- alzheimer
- brain
- diagnosis
- receptor protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 title 1
- 102000000853 LDL receptors Human genes 0.000 title 1
- 108010001831 LDL receptors Proteins 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 210000004556 brain Anatomy 0.000 abstract 3
- 230000008499 blood brain barrier function Effects 0.000 abstract 2
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 abstract 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 abstract 1
- 230000001010 compromised effect Effects 0.000 abstract 1
- 230000003511 endothelial effect Effects 0.000 abstract 1
- 210000003038 endothelium Anatomy 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000001839 systemic circulation Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20642800P | 2000-05-23 | 2000-05-23 | |
| US60/206,428 | 2000-05-23 | ||
| US24626800P | 2000-11-06 | 2000-11-06 | |
| US60/246,268 | 2000-11-06 | ||
| PCT/US2001/016561 WO2001090758A2 (fr) | 2000-05-23 | 2001-05-23 | Role du systeme vasculaire cerebral et du transport a travers la barriere hemato-encephalique dans la clairance du peptide beta-amyloide d'alzheimer dans le systeme nerveux central |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001264801A1 true AU2001264801A1 (en) | 2001-12-03 |
Family
ID=26901346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001264801A Abandoned AU2001264801A1 (en) | 2000-05-23 | 2001-05-23 | Diagnosis of alzheimer's disease ldl receptor protein-1 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7695903B2 (fr) |
| EP (1) | EP1290451B1 (fr) |
| JP (1) | JP4851676B2 (fr) |
| AT (1) | ATE312354T1 (fr) |
| AU (1) | AU2001264801A1 (fr) |
| CA (1) | CA2408566A1 (fr) |
| DE (1) | DE60115638T2 (fr) |
| WO (1) | WO2001090758A2 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| US6797276B1 (en) | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
| US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
| JP4851676B2 (ja) * | 2000-05-23 | 2012-01-11 | ザ ユニバーシティ オブ サザン カリフォルニア | アルツハイマー病におけるｌｄｌレセプタータンパク質１（ｌｒｐ−１）の役割 |
| DK1372708T3 (da) | 2001-02-13 | 2008-10-20 | Us Gov Sec Army | Vaccine til transkutan immunisering mod rejsediarre |
| AU2003253014A1 (en) * | 2002-06-21 | 2004-01-06 | Innogenetics N.V. | Method for the diagnosis and differential diagnosis of neurological diseases |
| WO2005122712A2 (fr) * | 2003-06-11 | 2005-12-29 | Socratech L.L.C. | Derive soluble de la proteine liee au recepteur de lipoproteine de basse densite de liaison directe au peptide amyloide beta d'alzheimer |
| ES2332846B1 (es) | 2007-10-26 | 2010-07-08 | Grifols, S.A. | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. |
| US8946165B2 (en) * | 2008-09-29 | 2015-02-03 | The Regents Of The University Of California | Compounds for reversing and inhibiting protein aggregation, and methods for making and using them |
| EP2488550A4 (fr) * | 2009-10-17 | 2013-03-06 | Zz Alztech Llc | Protéine mutante apparentée au récepteur ldl (lipoprotéine basse densité) ayant une capacité de liaison accrue au peptide amyloïde-bêta dans la maladie d'alzheimer |
| ES2950415T3 (es) * | 2019-01-10 | 2023-10-09 | Hospital Alvaro Cunqueiro Bloque Tecnico | Método in vitro para el diagnóstico o pronóstico de trastornos neurodegenerativos |
| CN110192859B (zh) * | 2019-05-05 | 2020-05-19 | 兰月 | 一种磁共振测量人脑类淋巴通路清除效率的方法 |
| KR102549828B1 (ko) * | 2021-03-22 | 2023-07-04 | 경희대학교 산학협력단 | Bbb-온-칩 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766856A (en) | 1984-03-19 | 1998-06-16 | The Picower Institute For Medical Research | Diagnostic method for evaluating advanced glycosylation endproducts using MAC-2 receptor |
| US4758583A (en) | 1984-03-19 | 1988-07-19 | The Rockefeller University | Method and agents for inhibiting protein aging |
| US4900747A (en) | 1984-03-19 | 1990-02-13 | The Rockefeller University | Method and agents for removing advanced glycosylation endproducts |
| US5202424A (en) | 1984-03-19 | 1993-04-13 | The Rockefeller University | Mesangial cell-derived receptors for advanced glycosylation endproducts and uses thereof |
| DE69321893T2 (de) * | 1992-07-22 | 1999-05-12 | Mclean Hospital Corp | Verfahren zum Nachweis von Alzheimer-Krankheit |
| US6410598B1 (en) | 1994-02-03 | 2002-06-25 | Michael P. Vitek | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
| US5861238A (en) | 1995-04-05 | 1999-01-19 | The Picower Institute For Medical Research | Methods for partitioning advanced glycosylation endproducts |
| US6156311A (en) | 1995-07-27 | 2000-12-05 | The American National Red Cross | Modulators of expression and function of LRP in alzheimer's disease |
| WO1997004794A1 (fr) * | 1995-07-27 | 1997-02-13 | The American National Red Cross | Modulateurs d'expression et de fonction de la proteine associee au recepteur de la lipoproteine basse densite (lrp) dans la maladie d'alzheimer |
| US5864018A (en) | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
| US6472140B1 (en) | 1997-09-05 | 2002-10-29 | The General Hospital Corporation | α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease. |
| US6413512B1 (en) | 1998-02-13 | 2002-07-02 | National Enzyme Company | Composition and method for treating disease by increasing activated α2 macroglobulin in the blood and extravascular tissue |
| JP4851676B2 (ja) * | 2000-05-23 | 2012-01-11 | ザ ユニバーシティ オブ サザン カリフォルニア | アルツハイマー病におけるｌｄｌレセプタータンパク質１（ｌｒｐ−１）の役割 |
| US6825164B1 (en) | 2000-08-14 | 2004-11-30 | The Trustees Of Columbia University In The City Of New York | Method to increase cerebral blood flow in amyloid angiopathy |
| US20040115671A1 (en) * | 2001-01-18 | 2004-06-17 | Zlokovic Berislav V | Gene expression profiling of endothelium in alzheimer's disease |
| EP1532258A4 (fr) * | 2002-06-11 | 2006-11-02 | Socratech L L C | Traitement du dysfonctionnement vasculaire et maladie d'alzheimer |
-
2001
- 2001-05-23 JP JP2001586471A patent/JP4851676B2/ja not_active Expired - Fee Related
- 2001-05-23 US US10/296,168 patent/US7695903B2/en not_active Expired - Fee Related
- 2001-05-23 DE DE60115638T patent/DE60115638T2/de not_active Expired - Lifetime
- 2001-05-23 CA CA002408566A patent/CA2408566A1/fr not_active Abandoned
- 2001-05-23 EP EP01939264A patent/EP1290451B1/fr not_active Expired - Lifetime
- 2001-05-23 WO PCT/US2001/016561 patent/WO2001090758A2/fr not_active Ceased
- 2001-05-23 AU AU2001264801A patent/AU2001264801A1/en not_active Abandoned
- 2001-05-23 AT AT01939264T patent/ATE312354T1/de not_active IP Right Cessation
-
2004
- 2004-03-08 US US10/794,425 patent/US20040259159A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004510957A (ja) | 2004-04-08 |
| EP1290451A2 (fr) | 2003-03-12 |
| EP1290451B1 (fr) | 2005-12-07 |
| US20050239062A1 (en) | 2005-10-27 |
| US20040259159A1 (en) | 2004-12-23 |
| WO2001090758A2 (fr) | 2001-11-29 |
| WO2001090758A3 (fr) | 2002-08-29 |
| JP4851676B2 (ja) | 2012-01-11 |
| US7695903B2 (en) | 2010-04-13 |
| ATE312354T1 (de) | 2005-12-15 |
| DE60115638D1 (de) | 2006-01-12 |
| DE60115638T2 (de) | 2006-08-17 |
| CA2408566A1 (fr) | 2001-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001264801A1 (en) | Diagnosis of alzheimer's disease ldl receptor protein-1 | |
| Mourad et al. | Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach | |
| BG104075A (en) | Combined treatment including atorvastatin and an antihypertonic form | |
| CA2468771A1 (fr) | Composition pharmaceutique pour une utilisation ophtalmologique et rhinologique | |
| EP1679080A3 (fr) | Prévention et traitement de maladie amyloidogène | |
| NO20015758D0 (no) | Forebygging og behandling av amyloidogen sykdom | |
| DE60003160D1 (de) | Kombinationen von formoterol und mometasonfuroat | |
| ATE339954T1 (de) | Kombinationen von formoterol und tiotropium-salz | |
| MA29273B1 (fr) | Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur | |
| SE9704644D0 (sv) | New use | |
| Cheung et al. | Assessing duration of antihypertensive effects with whole-day blood pressure monitoring | |
| Warner et al. | Enoxaparin: in the prevention of venous thromboembolism in medical patients | |
| Kocsis et al. | Pharmacotherapy for ‘pure’dysthymia: setraline vs. imipramine and placebo | |
| DE50005282D1 (de) | Medikament sowie aufeinander abgestimmte kombination von medikamenten | |
| US20250000818A1 (en) | New synergistic combinations based on fenm and an acetylcholinesterase inhibitor | |
| Israili | The use of calcium antagonists in the therapy of hypertension in the elderly | |
| Chobanian | Current Use of Diuretics in the Management of Hypertension | |
| Richardson | Can physicians effect persistent control of blood pressure? | |
| Mahavadi | Autophagy in Amiodarone induced Lung Fibrosis: A Close Look | |
| Rocha-Gonsalves et al. | First clinical experience with isradipine in the treatment of hypertension in Portugal | |
| Shashkov et al. | Pharmacological prophylaxis of vestibulo-autonomous syndrome (motion sickness) in model investigations | |
| Bangalore et al. | Perioperative β blockade | |
| Michalewiz et al. | Primary Prevention of Cardiovascular Disease Endpoints Using β-Blockers | |
| Costabel | Current concepts of the management of sarcoidosis | |
| Wang et al. | Hypertension in the elderly: insights from recent research |